JPWO2022071578A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022071578A5
JPWO2022071578A5 JP2022554145A JP2022554145A JPWO2022071578A5 JP WO2022071578 A5 JPWO2022071578 A5 JP WO2022071578A5 JP 2022554145 A JP2022554145 A JP 2022554145A JP 2022554145 A JP2022554145 A JP 2022554145A JP WO2022071578 A5 JPWO2022071578 A5 JP WO2022071578A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
esaxerenone
pharma
acceptable salt
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022554145A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022071578A1 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2021/036423 external-priority patent/WO2022071578A1/ja
Publication of JPWO2022071578A1 publication Critical patent/JPWO2022071578A1/ja
Publication of JPWO2022071578A5 publication Critical patent/JPWO2022071578A5/ja
Pending legal-status Critical Current

Links

JP2022554145A 2020-10-02 2021-10-01 Pending JPWO2022071578A1 (https=)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020167891 2020-10-02
PCT/JP2021/036423 WO2022071578A1 (ja) 2020-10-02 2021-10-01 ミネラルコルチコイド受容体拮抗剤と、ｓｇｌｔ２阻害剤の組み合わせ医薬

Publications (2)

Publication Number Publication Date
JPWO2022071578A1 JPWO2022071578A1 (https=) 2022-04-07
JPWO2022071578A5 true JPWO2022071578A5 (https=) 2024-09-24

Family

ID=80951710

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022554145A Pending JPWO2022071578A1 (https=) 2020-10-02 2021-10-01

Country Status (2)

Country Link
JP (1) JPWO2022071578A1 (https=)
WO (1) WO2022071578A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023331475A1 (en) * 2022-09-01 2025-04-17 Astrazeneca Ab Combination of sglt2 inhibitors and mineralcorticoid receptor modulators for use in treatment of cardiorenal diseases
EP4663203A1 (en) * 2023-02-08 2025-12-17 East China University of Science and Technology Combination of sglt2 inhibitor and menthol and use thereof in treatment of heart disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2847904T3 (es) * 2013-07-23 2021-08-04 Daiichi Sankyo Co Ltd Medicamento para la prevención o el tratamiento de la hipertensión
CN108778334A (zh) * 2016-03-24 2018-11-09 第三共株式会社 用于治疗肾脏疾病的药物

Similar Documents

Publication Publication Date Title
AU2021282491B2 (en) Treatment or prevention of cardiovascular events via the administration of a colchicine derivative
EP2419097B1 (en) Pharmaceutical composition comprising (1s)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-d-glucitol and metformin and uses thereof in the treatment of diabetes
HRP20200828T1 (hr) Farmaceutski pripravak koji sadrži sglt2-inhibitor, dpp-iv-inhibitor i prema potrebi jedno dodatno antidijabetičko sredstvo, te njegove uporabe
JP6358515B2 (ja) Ｓｇｌｔ２阻害薬と抗高血圧薬との組み合わせ
HRP20250931T1 (hr) Pripravak za upotrebu u postupku liječenja prekomjerne težine i pretilosti kod pacijenata s visokim kardiovaskularnim rizikom
WO2016159577A2 (ko) 1,2 나프토퀴논 유도체 및 이의 제조방법
JPWO2022071578A5 (https=)
Karakasis et al. Sodium-glucose cotransporter-2 inhibitors in patients with acute coronary syndrome: a modern cinderella?
Mizuma et al. Clinical perspectives on ischemic stroke
JP2022529208A5 (https=)
TW200817000A (en) New paediatric indications for direct thrombin inhibitors
EP1263435B1 (en) Pharmaceutical composition for treatment and prevention of liver fibrosis and cirrhosis
CN104703602B (zh) 1‑金刚烷乙氧基‑3‑吗啉基‑2‑丙醇或其药学上可接受的盐的药物组合物用于治疗心血管病变
Fedacko et al. Coenzyme Q10 in heart and brain diseases
TOLBA et al. THEEFFECT OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS ON CARDIOVASCULAR DISEASE RISK IN TYPE 2 DIABETES MELLITUS
JP2004511433A (ja) 末梢血管疾患、末梢ニューロパシー、及び自律性ニューロパシーの処置方法
CN103948620B (zh) 一种含有山栀苷甲酯的药物组合物及应用
Kohli Linagliptin and Dapagliflozin: Therapeutic Applicability in T2DM with High CV Risk
WO2019027459A1 (en) PROLONGED RELEASE OF NITRIC OXIDE INTO THE INTESTINAL TRACT
HK1158984A (en) Use of dronedarone for the preparation of a medicament for the prevention of stroke or transient ischemic attack